NASDAQ:PGNY Progyny (PGNY) Stock Price, News & Analysis $14.49 +0.15 (+1.05%) (As of 05:45 PM ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Progyny Stock (NASDAQ:PGNY) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Progyny alerts:Sign Up Key Stats Today's Range$14.11▼$14.6150-Day Range$13.67▼$17.1852-Week Range$13.39▼$42.08Volume1.54 million shsAverage Volume1.43 million shsMarket Capitalization$1.23 billionP/E Ratio24.98Dividend YieldN/APrice Target$25.00Consensus RatingHold Company OverviewProgyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides assistance service programs where various services can be offered through a reimbursement program, including adoption, surrogacy, doula, and travel reimbursement when travel is required to receive medical services. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.Read More… Progyny Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks76th Percentile Overall ScorePGNY MarketRank™: Progyny scored higher than 76% of companies evaluated by MarketBeat, and ranked 248th out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.2 / 5Analyst RatingHold Consensus RatingProgyny has received a consensus rating of Hold. The company's average rating score is 2.31, and is based on 4 buy ratings, 9 hold ratings, and no sell ratings.Amount of Analyst CoverageProgyny has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Progyny's stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth8.47% Earnings GrowthEarnings for Progyny are expected to grow by 8.47% in the coming year, from $0.59 to $0.64 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Progyny is 24.98, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 112.36.Price to Earnings Ratio vs. SectorThe P/E ratio of Progyny is 24.98, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 87.05.Price to Earnings Growth RatioProgyny has a PEG Ratio of 1.64. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioProgyny has a P/B Ratio of 2.51. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted15.78% of the float of Progyny has been sold short.Short Interest Ratio / Days to CoverProgyny has a short interest ratio ("days to cover") of 5.1.Change versus previous monthShort interest in Progyny has recently decreased by 0.09%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldProgyny does not currently pay a dividend.Dividend GrowthProgyny does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted15.78% of the float of Progyny has been sold short.Short Interest Ratio / Days to CoverProgyny has a short interest ratio ("days to cover") of 5.1.Change versus previous monthShort interest in Progyny has recently decreased by 0.09%, indicating that investor sentiment is improving. News and Social Media1.5 / 5News Sentiment0.66 News SentimentProgyny has a news sentiment score of 0.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Progyny this week, compared to 6 articles on an average week.Search InterestOnly 4 people have searched for PGNY on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Progyny insiders have not sold or bought any company stock.Percentage Held by Insiders12.30% of the stock of Progyny is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions94.93% of the stock of Progyny is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Progyny's insider trading history. Receive PGNY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Progyny and its competitors with MarketBeat's FREE daily newsletter. Email Address PGNY Stock News HeadlinesPGNY Stockholders: Robbins LLP is Investigating the Officers and Directors of Progyny, Inc. to Determine if They Breached Fiduciary Duties Owed to ShareholdersDecember 18, 2024 | prnewswire.comJohnson Fistel has Commenced an Investigation on Behalf of Progyny (PGNY) ShareholdersDecember 18, 2024 | globenewswire.comMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.December 23, 2024 | Brownstone Research (Ad)Progyny, Inc. (NASDAQ:PGNY) Receives $25.00 Average PT from AnalystsDecember 13, 2024 | americanbankingnews.comRobbins LLP Informs Progyny, Inc. Stockholders that it is Investigating the Officers and Directors of PGNY to Determine if They Breached Fiduciary Duties Owed to ShareholdersDecember 11, 2024 | globenewswire.comJohnson Fistel has Commenced an Investigation on Behalf of Progyny (PGNY) ShareholdersDecember 3, 2024 | globenewswire.comJP Morgan Downgrades Progyny (PGNY)December 3, 2024 | msn.comProgyny downgraded to Neutral from Overweight at JPMorganDecember 2, 2024 | markets.businessinsider.comSee More Headlines PGNY Stock Analysis - Frequently Asked Questions How have PGNY shares performed this year? Progyny's stock was trading at $37.18 on January 1st, 2024. Since then, PGNY stock has decreased by 61.0% and is now trading at $14.49. View the best growth stocks for 2024 here. How were Progyny's earnings last quarter? Progyny, Inc. (NASDAQ:PGNY) released its quarterly earnings results on Tuesday, November, 12th. The company reported $0.11 earnings per share for the quarter, missing analysts' consensus estimates of $0.37 by $0.26. Progyny's revenue for the quarter was up 2.0% compared to the same quarter last year. When did Progyny IPO? Progyny (PGNY) raised $150 million in an initial public offering on Friday, October 25th 2019. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs and BofA Merrill Lynch acted as the underwriters for the IPO and Citigroup, Piper Jaffray, SVB Leerink and TPG Capital were co-managers. Who are Progyny's major shareholders? Top institutional shareholders of Progyny include State Street Corp (3.66%), International Assets Investment Management LLC (2.84%), Pacer Advisors Inc. (2.76%) and Fred Alger Management LLC (2.16%). Insiders that own company stock include Tpg Gp A, Llc, Michael E Sturmer, Norman Payson, Peter Anevski, David J Schlanger, Mark S Livingston, Cheryl Scott and Kevin K Gordon. View institutional ownership trends. How do I buy shares of Progyny? Shares of PGNY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Progyny own? Based on aggregate information from My MarketBeat watchlists, some other companies that Progyny investors own include Humana (HUM), American Water Works (AWK), NVIDIA (NVDA), Rambus (RMBS), Voyager Therapeutics (VYGR), Saia (SAIA) and Waste Connections (WCN). Company Calendar Last Earnings11/12/2024Today12/23/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Miscellaneous health & allied services, not elsewhere classified Sub-IndustryN/A Current SymbolNASDAQ:PGNY CUSIPN/A CIK1551306 Webwww.progyny.com Phone212-888-3124FaxN/AEmployees563Year Founded2008Price Target and Rating Average Stock Price Target$25.00 High Stock Price Target$43.00 Low Stock Price Target$17.00 Potential Upside/Downside+72.5%Consensus RatingHold Rating Score (0-4)2.31 Research Coverage13 Analysts Profitability EPS (Most Recent Fiscal Year)$0.58 Trailing P/E Ratio24.98 Forward P/E Ratio24.56 P/E Growth1.64Net Income$62.04 million Net Margins5.03% Pretax Margin7.18% Return on Equity11.36% Return on Assets7.87% Debt Debt-to-Equity RatioN/A Current Ratio2.62 Quick Ratio2.62 Sales & Book Value Annual Sales$1.14 billion Price / Sales1.08 Cash Flow$0.67 per share Price / Cash Flow21.77 Book Value$5.77 per share Price / Book2.51Miscellaneous Outstanding Shares85,153,000Free Float74,679,000Market Cap$1.23 billion OptionableOptionable Beta1.35 Social Links The 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NASDAQ:PGNY) was last updated on 12/23/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Progyny, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Progyny With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.